Toshima-ku, Tokyo, Japan (Received for publication September 27, 1975) Several derivatives of mycophenolic acid (MA) were tested for their antitumor activity against leukemia L-1210 when administered orally and carbamoyl mycophenolic acid ethylester (CMAE) was selected as the most active antitumor agent in these tests. An oral administration of CMAE also inhibited the growth of EHRLICH solid carcinoma, NF sarcoma, myeloma X-5563 and sarcoma 180 in mice. In comparison with antitumor activity of MA, the improvement in activity of CMAE against leukemia L-1210 and EHRLICH solid carcinoma was indeed remarkable.
CMAE seems to be less immunosuppressive than MA.
As reported by several workers,'.',') mycophenolic acid (MA) is effective by oral administration as well as by parenteral administration. We previously reported that some derivatives of MA possess higher suppressive effect on leukemia L-1210 (L-1210) than the parent compound on intraperitoneal administration.') In this paper, we will describe the process of selection of an orally active antitumor agent, carbamoyl mycophenolic acid ethylester with antitumor activity against several experimental tumors in mice. Materials and Method Agents. MA and its derivatives were purified or synthesized and supplied by the Department of Synthetic Organic Chemistry of our Institute. 5-rluorouracil (5rU), 6-mercaptopurine (6MP) and cyclophosphamide (CPA) were obtained commercially. These agents were dissolved in saline or suspended in 0.25 % carboxymethylcellulose-saline and they were administered orally (0.2 ml/mouse).
Evaluation of antitumor activity. Unless otherwise stated agents were administered orally once daily for 5 days starting 18 hours after inoculation of tumors. Test systems with L-1210, EHRLICH solid carcinoma (ESC) and X-5563 plasma cell myeloma (X-5563) and evaluation of activities in these systems were described in the preceding paper.') Minced NF sarcoma (NFS) (10 mg/mouse) was transplanted subcutaneously to ddy/S mice (4 week-old, male). Sarcoma 180 ascites tumor cells (5 x 108 cells/mouse) were inoculated by the same route into the same strain of mice. Antitumor activity was evaluated by the tumor weight ratios (treated /control x100) on the 10th day after tumor inoculation both in the NF sarcoma and in the sarcoma 180 solid tumor (S-180).
In the L-1210 system, optimal dose (OD) was obtained from MaxILS (maximum increase in life span). ILS30 (30 % increase life span dose) was obtained graphically. Chemotherapeutic ratio (CR) was calculated by the formula: CR=OD/ILS30.
Acute toxicity of agent was calculated by a single oral administration to ddy/S mice, and from the number of survivors on the 10th day after the injection (method of LITCHFIELDWILCOxoN). LD,, with 5 daily consecutive oral administrations was also obtained and used as the maximum tolerable dose (MTD) for the evaluation of antitumor activities of agents. Activities of various dosage levels against L-1210 are shown in Table 6 . In the group treated with 900 mg/kg of CMAE, mice died due to toxicity of the agent. MaxILS (T/C in Table 6 ) was obtained with 500 mg/kg dose. There was no detectable activity at the 50 mg/kg 
Dose (mg/kg) and T/C* 900 high as at 2,000 mg/kg. On the other hand, the 1-, 3-and 5-days schedule resulted in the best CR value.
Route of Administration.
The activity of CMAE against L-1210 by intraperitoneal administration is presented in Table 8 . These results are in agreement with those earlier results reported previously'' and they are higher than those obtained with oral administration.
Toxicity.
Acute toxicity tests were carried out in mice (Tables 9 and 10 ). The LD60 by single oral administration and the LD10 by 5 consecutive daily oral administrations were 3,080 and 360 mg/kg, respectively: the corresponding values for MA are 2,500 and 220 mg/kg. CMAE is apparently less toxic than MA. Minced COK tumor (10 mg/mouse) were transplanted subcutaneously to allogenic mice (ddy/S). showed only a suppressive effect on growth of the tumor, whereas 6MP and MA showed enhancement of the tumor growth indicating a lack of immunosuppressive activity with CMAE.
When the antitumor activity of CMAE was compared with MA, CMAE has greater activities against ESC and particularly against L-1210. Our data suggest that the antitumor spectrum of CMAE may be different from that of CPA, CMAE is more effective than CPA in the ESC system, whereas CPA is more effective against NFS and X-5563 systems.
Our results suggest that CMAE may be a useful orally active antitumor agent.
